Search results for: Precision Medicine
Filter search results
How Restrictive are NICE ‘Optimised’ Decisions?
27 April 2023
…through their Technology Appraisal (TA) programme. The main decision outcomes are to ‘recommend’ the medicine (in line with marketing authorisation), ‘not recommend’ the medicine, or something in between: ‘optimised’. Optimised…
What is the future of health economics?
1 May 2023
…Hygiene and Tropical Medicine John Cairns, Professor of Health Economics at the London School of Hygiene and Tropical Medicine, is pondering what’s next for his discipline and where it is…
Capturing the Unexpected Benefits of Medical Research
5 January 2001
…This is true for long established medicines, for example the cardiovascular benefits of… It has long been known that a medicine may turn out to have an unexpected beneficial effect…
OHE Annual Lecture: Universal Health Coverage: the Holy Grail?
8 June 2014, 11:00pm
…2006 she was awarded a CBE for services to medicine and elected a Foreign Associate of the US Institute of Medicine. In 2009 she was elected Fellow of the UK…
Innovative Competition in Medicine
1 January 1992
It is almost twenty years since I realised the significance of Schumpeter’s work to the pharmaceutical industry. But since the references to his conclusions in ‘The Canberra hypothesis’ in 1975,…
Around The World in HTAs: France – Three Core HTA Values
12 March 2026
…services such as certain medicines and medical devices, subject to out-of-pocket payments and/or supplementary insurance. As a country that spends a significant proportion of its national income on healthcare (around 12% of…
Using MCDA to Assess the Value of Treatments for Rare Diseases
5 December 2013
…(OHE) and its collaborators, medicines for rare disease may be effectively valued using an innovative approach — multi-criteria decision analysis (MCDA) — that can include all relevant stakeholders, including patients’…
Spotlight on OHE: Adaptive Pathways, Economic Evaluation, Stated Preferences and Life-cycle Price Modelling
5 November 2014
Medicines Adaptive Pathways: A Practical Strategy to Improve Patient Access to Medicines? In September 2014 the Centre for Innovation in Regulatory Science held a workshop with invited regulators, health…
Around The World in HTAs: The Slovak Republic – Valuing the Future
13 September 2023
…process should take 180 days from submission to decision for a new medicine and 270 days for medicines that are already reimbursed but require a new assessment process (for example,…